Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER-HF pre-discharge versus post-discharge sacubitril/valsartan initiation study
2015-003266-87Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF) and heart failure (HF) (2 arms), sponsored by Novartis. Primary endpoints: 10-week up-titration success and Achievement of target dose by week 10. Started Dec 2015; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure (HF)
Beyond the preview
Go deeper on 2015-003266-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003266-87.